Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas

Cancer

Volumn 77, Issue 6, 1996, Pages 1180-1188

  Czader, Magdalena ^a   Mazur, Joanna ^b   Pettersson, Mikael ^a   Liliemark, Jan ^a   Strömberg, Mats ^a   Christensson, Birger ^a   Tribukait, Bernard ^a   Auer, Gert ^a   Öst, Åke ^a   Porwit, Anna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSTITUTE OF MOTHER AND CHILD   (Poland)

Author keywords

apoptosis; centroblastic centrocytic; DNA ploidy; non Hodgkin's lymphoma; proliferation; S phase

Indexed keywords

CYCLOPHOSPHAMIDE; DEOXYADENOSINE TRIPHOSPHATE; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY KI 67; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH; TUMOR REGRESSION;

EID: 13344294364     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1180::AID-CNCR26>3.0.CO;2-X     Document Type: Article

References (51)

1. Harris N, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
2. Tsujimoto T, Cossman J, Jaffe E, Croce C. Involvement of bcl-2 gene in human follicular lymphoma. Science 1985; 288:1440.
3. Morrison VA, Peterson BA. Combination chemotherapy in the treatment of follicular low-grade lymphoma. Leukemia Lymphoma 1993;10:29-33.
4. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993;11:644-651.
5. Horning SJ. Low-grade lymphoma 1993: State of art. Ann Oncol 1994;5:S23-7.
6. Kimby E, Björkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, et al. Chorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994;5:S67-71.
7. Romaguera JE, McLauglin P, North E, Dixon D, Silvermintz KB, Garnsey RA, et al. Multivariate analysis of prognostic factors in stage-IV follicular low-grade lymphoma: A risk model. J Clin Oncol 1991;9:762-9.
8. Leonard RCF, Hayward RL, Prescott RJ, Wang JX. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Ann Oncol 1991;2:655-62.
9. The International non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
10. Bastion Y, Coiffier B. Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients? Ann Oncol 1994;12:1340-2.
11. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for Aggressive Lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994;12:1343-8.
12. Duque RE, Andreeff M, Braylan RC, Diamond RW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 1993; 14:492-6.
13. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, Stansfield AG. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphomas. J Pathol 1988;154:223-35.
14. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, et al. Independent prognostic significance of a nuclear antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki67. Blood 1988; 71:1157-60.
15. Kawauchi K, Sato Y, Furuya T, Watanabe S. Determination of proliferative fractions detected by immunohistochemistry with the monoclonal antibodies to bromodeoxyuridine and Ki-67 in malignant lymphomas. Hematol Oncol 1989;7:257-65.
16. Griffin NR, Howard MR, Quirke P, O'Brien CJ, Child JA, Bird CC. Prognostic indicators in centroblastic-centrocytic lymphoma. J Clin Pathol 1988;41:866-70.
17. Macartney JC, Camplejohn RS, Morris R, Hollowood K, Clarke D, Timothy A. DNA flow cytometry of follicular non-Hodgkin's lymphoma. J Clin Pathol 1991;44:215-8.
18. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
19. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
20. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Met Rev 1992;11:95-103.
21. Askew DA, Ashman RA, Simmons BC, Cleveland JL. Constitutive c-myc and IL-3-dependent myeloid cell line suppress cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-22.
22. Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Genet Dev 1994;4:120-9.
23. Hollowood K, Macartney JC. Reduced apoptotic cell death in follicular lymphoma. J Pathol 1991;163:337-42.
24. Del Vecchio MT, Leoncini L, Buerki K, Kraft R, Megha T, et al. Diffuse centrocytic and/or centroblastic malignant non-Hodgkin's lymphomas: Comparison of mitotic and pycnotic (apoptotic) indices. Int J Cancer 1991;47:38-43.
25. Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993;142:755-63.
26. Arends MJ, Harrison DJ. Apoptosis: Molecular aspects and pathological perspective. In: Molecular biology of histopathology. Crocker J, editor. Chichester, UK: John Wiley and Sons Ltd, 1994;121-35.
27. Kerr JFR, Wyllie AH, Currie AR. Apoptosis. In: Perspectives on mammalian cell death. Potten CS, editor. Oxford, UK: Oxford University Press, 1987;93-128.
28. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
29. Lennert K, Feller A. Histopathology of Non-Hodgkin's Lymphomas, 2nd edition. New York: Springer-Verlag, 1992.
30. Rosenberg SA and members of National Cancer Institute. Non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 1982;49:2112-35.
31. Christensson B, Tribukait B, Linder IL, Ullman B, Biberfeld P. Cell proliferation and DNA content in non-Hodgkin's lymphoma. Flow cytometry in relation to lymphoma classification. Cancer 1986;58:1295-1304.
32. Baisch H, Goehde W, Linden WA. Analysis of PCP-data to determine the fraction of cells in various phases of cell cycle. Radiat Environ Biophys 1975;12:31-9.
33. Czader M, Porwit A, Tani E, Öst Å, Mazur J, Auer G. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas. Modern Pathol 1995;8:51-8.
34. Braylan RC. Flow-cytometric DNA analysis in the diagnosis and prognosis of lymphoma. Am J Clin Pathol 1993;99:374-80
35. Rehn S, Glimelius B, Strang P, Sundström C, Tribukait B. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin's lymphoma. Hematol Oncol 1990;8:8-12.
36. Auer G, Caspersson TO, Wallgren AS. DNA content and survival in mammary carcinoma. Ann Quant Cytol Histol 1980;2:161-5.
37. Forsslund G, Eposti PL, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992;69:1432-9.
38. Moberger B, Auer G, Forsslund G, Moberger G. The prognostic significance of DNA measurements in endometrial carcinoma. Cytometry 1984;5:430-6.
39. Scharpe S, Jones DB, Wright DH. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br J Cancer 1987;55:283-6.
40. 3H]-thymidine labeling index and monoclonal antibody Ki-67 in non-Hodgkin's lymphomas. Hematol Oncol 1988;6:21.
41. Porwit A. Immunohistochemical methods in the studies of malignant lymphomas and immunopathology of HIV-infection (thesis). Stockholm: Karolinska Institute, 1988.
42. Wolfe JT, Pringle JH, Cohen GM. In situ end-labeling detects large DNA fragments (>30 kilobase pairs) in addition to oligonucleosomal fragments in apoptotic rat thymocytes (abstract). Kinsale, Ireland: European School of Hematology, 1994.
43. Eastman A, Barry MA. The origins of DNA breaks: A consequence of DNA damage, DNA repair, or apoptosis? Cancer Invest 1992;10:229-40.
44. Gorczyca W, Tuziak T, Kram A, Melamed MR, Darzynkiewicz Z. Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 1994;15:169-75.
45. Weaver V, Lach B, Walker PR, Sikorska M. Role of proteolysis in apoptosis: Involvement of serine proteases in internucleosomal DNA fragmentation in immature thymocytes. Biochem Cell Biol 1993;71:488-500.
46. Cohen GM, Sun XM, Snowden RT, Dinsdale D, Skiletter DN. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 1992;286:331-4.
47. Oberhammer F, Bursch W, Tiefenbacher R, Fröschl G, Pavelka M, Purchio T, et al. Apoptosis is induced by transforming growth factoi-β1 within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology 1993;18:1238-46.
48. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, et al. Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kilobase fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993;12:3679-84.
49. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-86.
50. Miyashita T, Reed JC. BCL-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticosteroids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407.
51. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy - induced apoptosis in a leukemia cell line. Blood 1993;81:151-7.